Jin & Investment Partners
VC Fund
Seongnam, South Korea
Jin & Investment Partners is an investment company that specializes in digital health care.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Jin & Investment Partners invests in
Stages Jin & Investment Partners invests in
Countries Jin & Investment Partners invests in
Investment Focus
Industry
- Biotechnology 3 (50%)
- Medical 2 (33%)
- Therapeutics 2 (33%)
- Pharmaceutical 2 (33%)
- Analytics 1 (17%)
Stage
- Series B 3 (50%)
- Series C 2 (33%)
- Seed 1 (17%)
Country
- South Korea 5 (83%)
- United States 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Trioar
|
Trioar is a biotechnological research company that manufacture pharmaceutical products and drugs. | $16.2M / Series B / Jul 17, 2025 | |
Nventric
|
Nventric is a medical device company that develops core products for neurovascular, coronary heart, and peripheral vascular applications. | $10.5M / Series B / Feb 06, 2024 | |
Ubix Therapeutics
|
Ubix Therapeutics is a research and development company that develops anti-cancer drugs. | $9.2M / Series C / Mar 28, 2023 | |
HAII
|
HAII is a theranostics companion platform that offers treatments developed by AI data analytics. | $5.6M / Series B / Nov 23, 2022 | |
Neona
|
Neona is a biotechnology company. It researches and develops anticancer drugs based on RNA. The company is also involved in developing macrophage activation-based immunotherapies, anticancer drugs targeting multiple tumor-causing genes, and anticancer drugs that regulate genes responsible for cell damage repair. | $2.2M / Seed / Apr 02, 2022 | |
Wellmarker Bio
|
Their Company has developed a biomarker-based cancer drugs based on accumulated developmental experience and know-how. They have a new drug development institute including synthetic and bio-research and management support center.Utilizing R&D infrastructure from Asan Medical Center in Seoul Republic of Korea they are focusing on developingnew drugs that overcome resistance of existing therapeutic approaches.Additionally they are focusing on developing first-in-class biomarker-based drugs for medical unmet needs in various cancers such as colon cancer, lung cancer and liver cancer. | $11.8M / Series C / Oct 14, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jin & Investment Partners invest in?
Jin & Investment Partners invests primarily in Biotechnology, Medical and Therapeutics startups, most often at Series B and Series C stage. Most of the 6 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Jin & Investment Partners last invest?
The most recent investment recorded for Jin & Investment Partners closed in Jul 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
